Page 89 - Read Online

Toniutto et al. Hepatoma Res 2020;6:50 I http://dx.doi.org/10.20517/2394-5079.2020.40 Page 19 of 21

with hepatocellular carcinoma. Transplantation 2007;83:893-9.
70. Shirabe K, Taketomi A, Morita K, Soejima Y, Uchiyama H, et al. Comparative evaluation of expanded criteria for patients with
hepatocellular carcinoma beyond the Milan criteria undergoing living-related donor liver transplantation. Clin Transplant 2011;25:E491-8.
71. Lee JH, Cho Y, Kim HY, Cho EJ, Lee DH, et al. Serum tumor markers provide refined prognostication in selecting liver transplantation
candidate for hepatocellular carcinoma patients beyond the Milan criteria. Ann Surg 2016;263:842-50.
72. Chaiteerakij R, Zhang X, Addissie BD, Mohamed EA, Harmsen WS, et al. Combinations of biomarkers and Milan criteria for predicting
hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2015;21:599-606.
73. Zheng Z, Zhou L, Gao S, Yang Z, Yao J, et al. Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and
meta-analysis. Int J Med Sci 2013;10:653-64.
74. An HJ, Jang JW, Bae SH, Choi JY, Yoon SK, et al. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver
transplantation in patients with hepatocellular carcinoma. Liver Transpl 2012;18:1406-14.
75. Kim YK, Kim SH, Lee SD, Hong SK, Park SJ. Pretransplant serum levels of C-reactive protein predict prognoses in patients undergoing
liver transplantation for hepatocellular carcinoma. Transplant Proc 2015;47:686-93.
76. Halazun KJ, Hardy MA, Rana AA, Woodland DCt, Luyten EJ, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after
liver transplantation for hepatocellular carcinoma. Ann Surg 2009;250:141-51.
77. Najjar M, Agrawal S, Emond JC, Halazun KJ. Pretreatment neutrophil-lymphocyte ratio: useful prognostic biomarker in hepatocellular
carcinoma. J Hepatocell Carcinoma 2018;5:17-28.
78. Xu ZG, Ye CJ, Liu LX, Wu G, Zhao ZX, et al. The pretransplant neutrophil-lymphocyte ratio as a new prognostic predictor after liver
transplantation for hepatocellular cancer: a systematic review and meta-analysis. Biomark Med 2018;12:189-99.
79. Lai Q, Melandro F, Larghi Laureiro Z, Giovanardi F, Ginanni Corradini S, et al. Platelet-to-lymphocyte ratio in the setting of liver
transplantation for hepatocellular cancer: a systematic review and meta-analysis. World J Gastroenterol 2018;24:1658-65.
80. Han S, Lee S, Yang JD, Leise MD, Ahn JH, et al. Risk of posttransplant hepatocellular carcinoma recurrence is greater in recipients with
higher platelet counts in living donor liver transplantation. Liver Transpl 2018;24:44-55.
81. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important
compartments for circulating vascular endothelial growth factor. Angiogenesis 2003;6:283-7.
82. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost 2011;9:237-49.
83. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011;11:123-34.
84. Bihari C, Rastogi A, Shasthry SM, Bajpai M, Bhadoria AS, et al. Platelets contribute to growth and metastasis in hepatocellular
carcinoma. APMIS 2016;124:776-86.
85. von Felden J, Villanueva A. Role of molecular biomarkers in liver transplantation for hepatocellular carcinoma. Liver Transpl
2020;26:823-31.
86. Nishida N, Nishimura T, Kaido T, Minaga K, Yamao K, et al. Molecular scoring of hepatocellular carcinoma for predicting metastatic
recurrence and requirements of systemic chemotherapy. Cancers (Basel) 2018;10.
87. Miltiadous O, Sia D, Hoshida Y, Fiel MI, Harrington AN, et al. Progenitor cell markers predict outcome of patients with hepatocellular
carcinoma beyond Milan criteria undergoing liver transplantation. J Hepatol 2015;63:1368-77.
88. Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, et al. Integrative transcriptome analysis reveals common molecular subclasses
of human hepatocellular carcinoma. Cancer Res 2009;69:7385-92.
89. Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, et al. Combining clinical, pathology, and gene expression data to predict recurrence
of hepatocellular carcinoma. Gastroenterology 2011;140:1501-12.e2.
90. Dvorchik I, Schwartz M, Fiel MI, Finkelstein SD, Marsh JW. Fractional allelic imbalance could allow for the development of an equitable
transplant selection policy for patients with hepatocellular carcinoma. Liver Transpl 2008;14:443-50.
91. Pagano D, Barbera F, Conaldi PG, Seidita A, Di Francesco F, et al. Role of allelic imbalance in predicting hepatocellular carcinoma (HCC)
recurrence risk after liver transplant. Ann Transplant 2019;24:223-33.
92. Yang Z, Zhou L, Wu LM, Xie HY, Zhang F, et al. Combination of polymorphisms within the HDAC1 and HDAC3 gene predict tumor
recurrence in hepatocellular carcinoma patients that have undergone transplant therapy. Clin Chem Lab Med 2010;48:1785-91.
93. Wu LM, Yang Z, Zhou L, Zhang F, Xie HY, et al. Identification of histone deacetylase 3 as a biomarker for tumor recurrence following
liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One 2010;5:e14460.
94. Zhang Q, Chen X, Zhou J, Zhang L, Zhao Q, et al. CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence
after liver transplantation in hepatocellular carcinoma patients. Cancer Biol Ther 2006;5:808-14.
95. Liese J, Peveling-Oberhag J, Doering C, Schnitzbauer AA, Herrmann E, et al. A possible role of microRNAs as predictive markers for the
recurrence of hepatocellular carcinoma after liver transplantation. Transpl Int 2016;29:369-80.
96. Nakano T, Chen IH, Wang CC, Chen PJ, Tseng HP, et al. Circulating exosomal miR-92b: Its role for cancer immunoediting and clinical
value for prediction of posttransplant hepatocellular carcinoma recurrence. Am J Transplant 2019;19:3250-62.
97. Sanchez-Lorencio MI, Ramirez P, Saenz L, Martinez Sanchez MV, De La Orden V, et al. Comparison of Two types of liquid biopsies in
patients with hepatocellular carcinoma awaiting orthotopic liver transplantation. Transplant Proc 2015;47:2639-42.
98. Pavel MC, Fuster J. Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: future directions. World J
Gastroenterol 2018;24:3626-36.
99. Cillo U, Burra P, Mazzaferro V, Belli L, Pinna AD, et al. A multistep, consensus-based approach to organ allocation in liver
transplantation: toward a “Blended Principle Model”. Am J Transplant 2015;15:2552-61.
100. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, et al. Recommendations for liver transplantation for hepatocellular carcinoma: